ACRS
BEARISH
$3.54
Live
Aclaris Therapeutics, Inc. · NASDAQ
Target $8.29
(+134.1%)
$1.05
52W Range
$4.89
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$428.65M
P/E
N/A
ROE
-50.2%
Profit margin
N/A
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
87%
ACRS exhibits severe financial distress despite a strong analyst consensus, as evidenced by a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The company reports negative profitability across all key margins, with a staggering -1724.63% operating margin and a -50.20% ROE, signaling deep operational inefficiency. Although the debt-to-equity ratio is low (0.02) and liquidity is strong (current ratio 3.36), the company's revenue has collapsed by 85.9% YoY, and it continues to burn cash with no free cash flow. The absence of a Graham Number and intrinsic value estimate underscores the lack of a reliable valuation anchor, while the stock trades at an inflated Price/Sales of 54.77, suggesting extreme speculative pricing. Despite a recent 126.9% 1-year return, the underlying fundamentals remain critically deteriorating.
Key Strengths
Strong liquidity with current and quick ratios of 3.36
Low debt-to-equity ratio of 0.02, indicating minimal leverage risk
Analyst consensus of 'strong_buy' with a target price of $8.29
Recent 1-year price appreciation of +126.9% suggests strong short-term momentum
Historical earnings surprise patterns show occasional positive deviations (e.g., +14.3%, +24.4%)
Key Risks
Piotroski F-Score of 1/9 indicates severe financial distress and operational failure
Revenue declined 85.9% YoY, signaling business contraction
Negative operating margin (-1724.63%) and ROE (-50.20%) reflect deep unprofitability
No free cash flow or operating cash flow data available, indicating cash burn
Price/Sales of 54.77 is extremely high, suggesting overvaluation relative to revenue
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
20
30
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative revenue and earnings growth, Extreme valuation multiples, Lack of profitability and cash flow, No dividend or earnings stability
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Low debt-to-equity ratio (0.02)
- High current and quick ratios (3.36)
Watchpoints
- No Graham Number or intrinsic value estimate
- Price/Sales of 54.77 is extremely high
- No P/E or PEG ratios available
- Trading at premium despite negative fundamentals
Future
20/100
Ref Growth rates
Positives
- Analyst target price of $8.29 implies strong upside potential
- Recent 1-year return of +126.9% indicates market optimism
Watchpoints
- Revenue growth down 85.9% YoY
- Earnings growth is negative and volatile
- No positive Q/Q or YoY EPS growth trend
- Recent earnings surprises are mostly negative
Past
30/100
Ref Historical trends
Positives
- Some historical quarters beat estimates (e.g., +14.3%, +24.4%)
- Earnings surprise average of -1.36% over last 4 quarters
Watchpoints
- 2024-02-27: EPS surprise of +94.8% but followed by massive decline
- 2025-02-27: Actual EPS of -$1.01 vs estimate of -$0.37 (surprise: -169.3%)
- 2024-11-06: Surprise of -1275.0% indicates extreme miss
- Most recent Q/Q EPS growth: -33.3%
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity (0.02)
- High current and quick ratios (3.36)
Watchpoints
- Piotroski F-Score of 1/9 (extreme weakness)
- No Altman Z-Score available, but F-Score indicates distress risk
- Negative ROE (-50.20%), ROA (-24.32%)
- Operating margin of -1724.63%
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength: 0/100
- Company is not generating profits to support dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.54
Analyst Target
$8.29
Upside/Downside
+134.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACRS and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
Primary
|
-85.2% | -56.5% | +126.9% | +81.5% | +4.4% | +15.7% |
|
ALT
Altimmune, Inc.
Peer
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
OVID
Ovid Therapeutics Inc.
Peer
|
-27.0% | -11.8% | +865.0% | +67.3% | +41.5% | +6.2% |
|
ASMB
Assembly Biosciences, Inc.
Peer
|
-54.7% | +80.2% | +165.0% | +28.7% | +2.8% | -0.6% |
ACR
Aclaris Therapeutics, Inc.
Primary
5Y
-85.2%
3Y
-56.5%
1Y
+126.9%
6M
+81.5%
1M
+4.4%
1W
+15.7%
ALT
Altimmune, Inc.
Peer
5Y
-80.3%
3Y
-68.4%
1Y
-32.7%
6M
-3.9%
1M
-24.4%
1W
-1.1%
AUN
Auna SA
Peer
5Y
-41.0%
3Y
-41.0%
1Y
-30.8%
6M
-9.7%
1M
+21.7%
1W
+22.2%
OVI
Ovid Therapeutics Inc.
Peer
5Y
-27.0%
3Y
-11.8%
1Y
+865.0%
6M
+67.3%
1M
+41.5%
1W
+6.2%
ASM
Assembly Biosciences, Inc.
Peer
5Y
-54.7%
3Y
+80.2%
1Y
+165.0%
6M
+28.7%
1M
+2.8%
1W
-0.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.42
PEG Ratio
N/A
P/B Ratio
4.14
P/S Ratio
54.77
EV/Revenue
43.22
EV/EBITDA
-4.57
Market Cap
$428.65M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1724.63%
Gross Margin
N/A
ROE
-50.2%
ROA
-24.32%
Growth
Revenue and earnings growth rates
Revenue Growth
-85.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
3.36
Strong
Quick Ratio
3.36
Excellent
Cash/Share
$0.75
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$-0.16
-17.1% surprise
2025-11-06
$-0.12
+14.3% surprise
2025-08-07
$-0.13
-1.3% surprise
Healthcare Sector Comparison
Comparing ACRS against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-50.2%
This Stock
vs
-101.52%
Sector Avg
-50.5%
(Below Avg)
Debt to Equity
0.02
This Stock
vs
3.4
Sector Avg
-99.4%
(Less Debt)
Revenue Growth
-85.9%
This Stock
vs
124.21%
Sector Avg
-169.2%
(Slower)
Current Ratio
3.36
This Stock
vs
4.56
Sector Avg
-26.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $428.65M | - | -50.2% | -% | $3.54 | |
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 | Compare |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | Compare |
|
OVID
Ovid Therapeutics Inc.
|
NEUTRAL | $416.84M | - | -17.5% | -240.1% | $2.76 | Compare |
|
ASMB
Assembly Biosciences, Inc.
|
NEUTRAL | $444.7M | - | -36.9% | -103.6% | $28.11 | Compare |
ACRS
Aclaris...
BEARISH
Mkt Cap
$429M
P/E
-
ROE
-50.2%
Price
$3.54
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 2,375 | - |
| 2026-02-03 | WALKER NEAL | Chief Executive Officer | Stock Award | 63,475 | - |
| 2026-02-03 | LOEROP JAMES | Officer | Stock Award | 20,875 | - |
| 2026-02-03 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 22,025 | - |
| 2026-02-03 | DAVIS HUGH M. | President | Stock Award | 18,675 | - |
| 2026-01-30 | LOEROP JAMES | Officer | Stock Award | 33,500 | - |
| 2026-01-30 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 14,750 | - |
| 2026-01-02 | WALKER NEAL | Chief Executive Officer | Stock Award | 29,150 | - |
| 2026-01-02 | LOEROP JAMES | Officer | Stock Award | 91,900 | - |
| 2026-01-02 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 94,450 | - |
| 2025-12-02 | DAVIS HUGH M. | President | Stock Award | 26,750 | - |
BALTHASER KEVIN J
Chief Financial Officer
2026-02-27
2,375 shares
WALKER NEAL
Chief Executive Officer
2026-02-03
63,475 shares
LOEROP JAMES
Officer
2026-02-03
20,875 shares
BALTHASER KEVIN J
Chief Financial Officer
2026-02-03
22,025 shares
DAVIS HUGH M.
President
2026-02-03
18,675 shares
LOEROP JAMES
Officer
2026-01-30
33,500 shares
BALTHASER KEVIN J
Chief Financial Officer
2026-01-30
14,750 shares
WALKER NEAL
Chief Executive Officer
2026-01-02
29,150 shares
LOEROP JAMES
Officer
2026-01-02
91,900 shares
BALTHASER KEVIN J
Chief Financial Officer
2026-01-02
94,450 shares
DAVIS HUGH M.
President
2025-12-02
26,750 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
HC Wainwright & Co.
2026-01-28
Buy
Buy
HC Wainwright & Co.
2026-01-21
Buy
Buy
HC Wainwright & Co.
2025-10-20
Buy
Buy
Past News Coverage
Recent headlines mentioning ACRS from our newsroom.
Newest → oldest
No matching news yet.